Quoted Micro 21 November 2022

AQUIS STOCK EXCHANGE EDX Medical (EDX) completed its reversal into shell TECC Capital in a deal valued at £12m and £1.2m was raised at 6p a share. The share price returned from suspension and increased by 64.1% to 5.25p, but it is still below the placing price. EDX Medical develops digital diagnostic products and service […]

Power Metals Resources #POW – Kalahari Key Acquisition Complete – Power Metal Now Holds 87.71% Interest. Molopo Farms Drilling Update

Power Metal Resources PLC (LON:POW),  the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces the completion of the transaction to increase the Company’s interest in Kalahari Key Mineral Exploration Pty Limited (“KKME” or “Kalahari Key”) further details of which were provided in the Company’s announcement of 3 November 2022 […]

#KAV Kavango Resources Plc – Publication of Prospectus

Further to the announcement of 24 October 2022 in which Kavango announced it had conditionally raised £3,000,000 before expenses by the issue of 166,666,660 new ordinary shares of £0.001 each in the capital of the Company (the “New Ordinary Shares”) at a price per share of 1.8 pence, the Company is pleased to announce that […]

#HVO hVIVO plc – Investors’ Chronicle

Building on decades of experience, hVIVO is currently the only CRO focused on challenge studies, providing world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary. hVIVO contract awards Since the release of interim results in early September, hVIVO has announced a massive £13.4mn contract with a US biotechnology client, a repeat customer, to test its respiratory syncytial virus antiviral candidate using hVIVO’s established RSV Human Challenge Study Model. Although difficult to assess the challenge study market, Liberum Capital estimates there are around 20 challenge studies conducted each year. Using the prevailing average contract size of £6.7mn, this indicates £100mn-£135mn of challenge study work each year, excluding any additional income through manufacturing and validating bespoke challenge agent. Around 60 per cent of hVIVO’s current order book relates to biotech customers and the balance relates to big pharma, with the group carrying out three active challenge studies for big pharma in the first half of 2022 and two full-service challenge studies with values exceeding £25mn. Moreover, hVIVO has signed up eight challenge studies with big pharma companies since 2018, 12  and all the big pharma clients are repeat customers. Improving financials Backed by a bumper order book and having booked £9mn of group revenue in July and August 2022, house broker FinnCap expects the group’s hVIVO division, which carries out the challenge studies, to grow revenue from £29.4mn last year to £42.5mn in 2022 and account for 82 per cent of its total revenue estimate of £51.1mn. Furthermore, taking account of challenge study contract wins, revenue from Venn Life, laboratory services and non-challenge studies, the brokerage estimates that £53mn of its 2023 revenue estimate of £56mn is already covered. SGS’s expertise is in performing influenza challenge studies, but it also has Malaria challenge, and RSV challenge models.

#POLB Poolbeg Pharma Plc- Capital Markets Day

17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm.   The event, which […]

#SVML Sovereign Metals Limited- TZMI Congress Presentation

Sovereign Metals Limited (Company) is pleased to advise that a presentation entitled ‘TZMI Congress Presentation’ is available to download from the Company’s website at: https://sovereignmetals.com.au/company-presentations/.   ENQUIRIES   Dr Julian Stephens (Perth) Managing Director +61(8) 9322 6322 Sam Cordin (Perth) +61(8) 9322 6322 Sapan Ghai (London) +44 207 478 3900     Nominated Adviser on […]

Quoted Micro 14 November 2022

AQUIS STOCK EXCHANGE First quarter trading at National Milk Records (NMRP) strengthened in all areas. Revenues increased by 4% to £5.98m. There was an 82% rise in genomic testing revenues to £151,000. Milk prices are expected to remain strong. The GenoCells services, which provide farmers with genomically driven individual animal cell count analysis, will be […]

November 2022 Investment Review – Alan Green talks to Ken Baksh

Stocks covered: Whitbread #WTB, Frontier IP #FIPP, Enquest Bond #ENQ2 & Georgia Capital #CGEO Investment Review Summary During the one-month period to 31stOctober 2022, major equity markets, as measured by the aggregate FTSE All – World Index, rose moderately, reducing the year-to-date loss to 22%, in $ terms. Chinese equities, however, bucked this upward trend, […]

Quoted Micro 7 November 2022

AQUIS STOCK EXCHANGE Cooks Coffee Company Ltd (COOK), which was already quoted on the New Zealand Stock Exchange, joined Access segment of Aquis on 2 November at 20p a share. The share price rose to 21.5p (20p/23p) by the end of the week. There were no trades during the week. The company owns the Esquires […]